PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Antisense therapy - Market size and forecast 2018-2023 • RNAi therapy - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY APPLICATION • Segmentation by application • Cardiovascular diseases • Cancer • Metabolic disorders PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Alnylam Pharmaceuticals • Bausch Health • Biogen • Sarepta Therapeutics PART 16: APPENDIX • Research methodology • List of abbreviations PART 17: EXPLORE TECHNAVIO   Exhibit 01: Global biologic therapeutics market Exhibit 02: Segments of global biologic therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: List of pipeline molecules for antisense and RNAi therapeutics Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Antisense therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Antisense therapy - Year-over-year growth 2019-2023 (%) Exhibit 22: RNAi therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: RNAi therapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Customer landscape Exhibit 26: Pipeline molecules for cancer treatment Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions) Exhibit 30: Americas - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in Americas Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ millions) Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in EMEA Exhibit 35: APAC - Market size and forecast 2018-2023 ($ millions) Exhibit 36: APAC - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in APAC Exhibit 38: Key leading countries Exhibit 39: Market opportunity Exhibit 40: Impact of drivers and challenges Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: Alnylam Pharmaceuticals - Vendor overview Exhibit 47: Alnylam Pharmaceuticals - Business segments Exhibit 48: Alnylam Pharmaceuticals - Organizational developments Exhibit 49: Alnylam Pharmaceuticals - Geographic focus Exhibit 50: Alnylam Pharmaceuticals - Key offerings Exhibit 51: Bausch Health - Vendor overview Exhibit 52: Bausch Health - Business segments Exhibit 53: Bausch Health - Organizational developments Exhibit 54: Bausch Health – Geographic focu Exhibit 55: Bausch Health - Segment focus Exhibit 56: Bausch Health - Key offerings Exhibit 57: Biogen - Vendor overview Exhibit 58: Biogen - Business segments Exhibit 59: Biogen - Organizational developments Exhibit 60: Biogen – Geographic focus Exhibit 61: Biogen - Key offerings Exhibit 62: Sarepta Therapeutics - Vendor overview Exhibit 63: Sarepta Therapeutics - Business segments Exhibit 64: Sarepta Therapeutics - Organizational developments Exhibit 65: Sarepta Therapeutics - Geographic focus Exhibit 66: Sarepta Therapeutics - Key offerings Exhibit 67: Validation techniques employed for market sizing Exhibit 68: List of abbreviations

Alnylam Pharmaceuticals Bausch Health Biogen Sarepta Therapeutics